What this covers: The hormonal and metabolic drivers of body composition, visceral fat, insulin sensitivity, and metabolic rate, beyond simple caloric deficit.
Test first: Establish a baseline including HbA1c, fasting insulin, fasting glucose, hs-CRP, IGF-1, and ApoB.
Research focus: GLP-1 and dual or triple incretin agonists, GH secretagogues for lipolysis, and mitochondrial peptides (MOTS-c, AOD-9604).
Key thing to know: The strongest evidence is for GLP-1 and incretin agonists; other approaches are earlier-stage. Interpret with a licensed provider.
What does this goal involve?
Fat loss research in a peptide context spans several connected areas.
Beyond caloric deficit: Fat-loss research goes beyond simple caloric deficit to the hormonal, metabolic, and cellular mechanisms behind how the body stores and mobilizes fat. It focuses on visceral fat (the metabolically active fat around internal organs), insulin sensitivity, and energy-balance signals. Total weight loss and visceral fat reduction are distinct outcomes in the research.
Research landscape: The fat-loss research landscape is currently led by GLP-1 and dual/triple incretin agonists, which have produced the largest weight-loss results seen in pharmaceutical trials. GH secretagogues are studied for body composition (fat loss with muscle preservation) through a different mechanism, and mitochondrial peptides like MOTS-c for metabolic efficiency. Insulin sensitivity is the common thread.
Biomarkers to establish before exploring this goal.
Research protocols for this goal area typically reference the following biomarkers as baseline context. Testing these first gives you and your healthcare provider the most relevant starting information.
Mandatory baseline before GLP-1 research; reflects 3-month glycemic control and metabolic health status,the primary efficacy endpoint in all major GLP-1 clinical trials.
The most sensitive early marker of insulin resistance,must be established before GH or GLP-1 protocols to understand the metabolic starting point.
Pairs with fasting insulin for HOMA-IR calculation,together they provide the most complete picture of insulin resistance status before any metabolic research protocol.
Elevated inflammation impairs metabolic function and blunts GH axis response,knowing baseline CRP informs whether anti-inflammatory support should precede metabolic protocols.
Baseline required before any GH secretagogue research,IGF-1 is the primary downstream marker confirming GH axis activity and the key monitoring metric throughout GH protocols.
Cardiovascular risk context for metabolic research; GLP-1 agonists show direct ApoB reduction in trials,establishing baseline ApoB captures this cardiovascular benefit alongside weight changes.
What does the research focus on for this goal?
Research for this goal concentrates on a few distinct compounds and pathways.
GLP-1 agonists: The most evidence-supported category for fat-loss research: semaglutide and tirzepatide showed 15–21% average body-weight reductions in large Phase 3 trials. The effect is driven mainly by appetite suppression via central GLP-1 receptor activation, plus slowed gastric emptying and improved insulin sensitivity. Cardiovascular and metabolic benefits are documented alongside weight loss.
GH secretagogues: A different mechanism: GH-driven lipolysis preferentially targets visceral fat while preserving lean mass. Tesamorelin studies document visceral fat reduction through this pathway, with FDA approval for lipodystrophy as the strongest clinical evidence. Sermorelin, Ipamorelin, and CJC-1295 are studied for similar body-composition effects in aging populations.
MOTS-c and AOD-9604: Mitochondrial and metabolic peptide research (MOTS-c, AOD-9604) focuses on cellular energy efficiency — how well mitochondria oxidize fat and how insulin-receptor sensitivity affects glucose disposal. This is an earlier research stage but a mechanistically distinct approach that targets root metabolic dysfunction, which is why it also appears in longevity research.
Peptides commonly researched for this goal.
The peptides below appear in research literature in connection with this goal. This is not a recommendation to use any of these compounds. Always consult a licensed healthcare provider.
GLP-1 agonist with large Phase 3 RCT data showing 15–17% average weight reduction,the most extensively studied peptide for fat loss in the modern research era.
Dual GIP/GLP-1 agonist showing up to 20.9% weight reduction in SURMOUNT trials,the largest pharmaceutical weight loss results recorded at time of publication.
Triple agonist (GLP-1/GIP/glucagon) in Phase 2 showing up to 24.2% weight reduction,the most potent incretin-class compound in the research pipeline; Phase 3 data pending.
FDA-approved GHRH analog with RCT data for visceral fat reduction,the only GH-axis compound with regulatory approval specifically for fat distribution, providing the strongest clinical evidence in this subcategory.
GH secretagogue studied for body composition improvement through GH elevation and downstream IGF-1 signaling,particularly researched for visceral fat reduction alongside muscle preservation in aging contexts.
Mitochondria-derived peptide studied for metabolic regulation and insulin sensitivity,research suggests exercise-mimetic effects on glucose disposal and fat oxidation efficiency.
Modified HGH fragment studied for lipolysis effects without IGF-1 elevation,an approach intended to separate the fat-mobilizing mechanism of GH from its anabolic growth-promoting effects.
What research protocols typically examine.
Timeline
GLP-1 research protocols typically run 16–72 weeks in trials,meaningful weight changes are documented from 4–8 weeks. GH secretagogue protocols run 3–6 months minimum before body composition changes are assessed via DEXA or imaging.
Monitoring
HbA1c, fasting insulin, fasting glucose, IGF-1 (for GH protocols), ApoB, body weight, and waist circumference. Advanced protocols add DEXA body composition scans at baseline and 3–6 month intervals.
Limitations
Most fat loss research is conducted in populations with obesity or metabolic disease,translation to lean individuals seeking optimization is less established. Rebound weight gain after protocol cessation is a documented finding in GLP-1 trial extensions.